Idalopirdine

Drug Profile

Idalopirdine

Alternative Names: Lu AE58054; LU-AE58054; SGS-518

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Lundbeck A/S; Otsuka Pharmaceutical
  • Class Antipsychotics; Benzylamines; Fluorobenzenes; Indoles; Nootropics; Phenyl ethers; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • No development reported Cognition disorders

Most Recent Events

  • 23 Jan 2017 Lundbeck and Otsuka completes the phase III STARBRIGHT trial in Alzheimer's disease (Adjunctive treatment) in USA, Australia, Brazil, Czech Republic, Germany, Israel, Mexico, South Korea, Serbia, Singapore, Slovakia, Spain, Switzerland, Turkey and United Kingdom (NCT02006654)
  • 01 Dec 2016 Lundbeck and Otsuka completes the phase III STARBEAM trial in Alzheimer's disease (Adjunctive treatment) in USA, Argentina, Brazil, Canada, Croatia, Czech Republic, Estonia, Finland, France, Israel, Italy, South Korea, Lithuania, Poland, Portugal, Hungary, Ireland, Taiwan and United Kingdom (NCT02006641)
  • 06 Oct 2016 Lundbeck and Otsuka completes the phase III STARSHINE trial (Adjunctive treatment) in Alzheimer's disease in USA, Argentina, Belgium, Bulgaria, Canada, Chile, Czech Republic, Denmark, France, Germany, Italy, Poland, Romania, South Africa, Spain, Sweden and Ukraine (NCT01955161, EudraCT2012-004763-45)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top